However, recombinant forms of NRG1 have shown promise in augmenting LV contractility in HF, with some undergoing early phase clinical trials;33,34 they have also shown promise in a rat diabetic cardiomyopathy model.35 A recent multiomics study of human HF also implicated myocardial Erbb2 signaling;36 our analysis extends this to people without HF, provides broader coverage of the ERBB receptor family, and includes outcome data. This evidence concerns the gene ERBB2 and diabetic cardiomyopathy.